Aimed Bio (KRX: 0009K0)
Who is buying Aimed Bio?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩2.6bn ($2M) of Aimed Bio, the 108th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩1.3bn ($1M) and retail investors net sold ₩1.4bn ($1M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.
Foreign investors hold 3.03% of Aimed Bio's listed shares (KRX ownership data as of Oct 13, 2026), up from 2.64% twenty sessions earlier.
The stock closed at ₩20,700 on Oct 13, 2026: -12.29% over 20 sessions, -64.06% year-to-date. The 52-week range is ₩17,400 – ₩80,200.
At ₩20,700 the stock trades at 191.67× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩20,700 | ₩-0.6bn | +₩0.2bn | +₩0.3bn |
| 2026-10-12 | ₩22,200 | +₩0.4bn | ₩-0.1bn | ₩-0.4bn |
| 2026-10-08 | ₩24,250 | ₩-0.2bn | ₩-0.2bn | +₩0.5bn |
| 2026-10-07 | ₩25,900 | ₩-0.0bn | +₩0.2bn | ₩-0.1bn |
| 2026-10-06 | ₩25,800 | ₩-0.6bn | +₩0.1bn | +₩0.4bn |
| 2026-10-02 | ₩24,800 | ₩-0.7bn | ₩-0.0bn | +₩0.7bn |
| 2026-10-01 | ₩25,450 | +₩2.1bn | +₩1.0bn | ₩-3.1bn |
| 2026-09-30 | ₩22,350 | +₩1.1bn | ₩-0.1bn | ₩-1.1bn |
| 2026-09-29 | ₩21,500 | ₩-0.6bn | ₩-0.4bn | +₩0.9bn |
| 2026-09-28 | ₩22,350 | +₩0.3bn | ₩-0.4bn | +₩0.1bn |
| 2026-09-23 | ₩21,400 | +₩0.6bn | ₩-0.2bn | ₩-0.3bn |
| 2026-09-22 | ₩21,200 | +₩0.6bn | ₩-0.6bn | +₩0.1bn |
| 2026-09-21 | ₩21,650 | +₩0.7bn | ₩-0.2bn | ₩-0.6bn |
| 2026-09-18 | ₩21,750 | ₩-0.6bn | ₩-0.0bn | +₩0.6bn |
| 2026-09-17 | ₩22,650 | ₩-0.1bn | ₩-0.2bn | +₩0.2bn |
| 2026-09-16 | ₩22,600 | +₩0.1bn | ₩-0.1bn | ₩-0.1bn |
| 2026-09-15 | ₩22,600 | +₩0.0bn | +₩0.3bn | ₩-0.3bn |
| 2026-09-14 | ₩22,150 | +₩0.3bn | ₩-0.3bn | ₩-0.0bn |
| 2026-09-11 | ₩22,650 | +₩0.0bn | ₩-0.8bn | +₩0.8bn |
| 2026-09-10 | ₩23,700 | ₩-0.4bn | +₩0.4bn | ₩-0.1bn |
| 2026-09-09 | ₩23,600 | +₩0.2bn | ₩-0.3bn | +₩0.0bn |
| 2026-09-08 | ₩23,700 | +₩0.2bn | ₩-0.3bn | +₩0.1bn |
| 2026-09-07 | ₩24,250 | +₩0.3bn | ₩-0.1bn | ₩-0.3bn |
| 2026-09-04 | ₩23,450 | +₩0.5bn | ₩-0.0bn | ₩-0.6bn |
| 2026-09-03 | ₩22,400 | +₩0.3bn | ₩-0.7bn | +₩0.3bn |
| 2026-09-02 | ₩23,200 | +₩1.0bn | ₩-0.6bn | ₩-0.3bn |
| 2026-09-01 | ₩23,750 | +₩0.5bn | ₩-1.1bn | +₩0.6bn |
| 2026-08-31 | ₩24,500 | +₩0.3bn | ₩-0.9bn | +₩0.5bn |
| 2026-08-28 | ₩25,100 | +₩0.3bn | ₩-0.9bn | +₩0.5bn |
| 2026-08-27 | ₩25,700 | +₩0.1bn | +₩0.1bn | ₩-0.2bn |
| 2026-08-26 | ₩25,400 | ₩-0.3bn | ₩-0.5bn | +₩0.9bn |
| 2026-08-25 | ₩26,000 | ₩-0.5bn | +₩0.2bn | +₩0.3bn |
| 2026-08-24 | ₩25,950 | +₩1.3bn | +₩0.4bn | ₩-1.7bn |
| 2026-08-21 | ₩24,500 | ₩-0.6bn | ₩-0.0bn | +₩0.7bn |
| 2026-08-20 | ₩26,450 | ₩-1.8bn | +₩0.3bn | +₩1.5bn |
| 2026-08-19 | ₩26,100 | +₩1.9bn | ₩-0.7bn | ₩-1.2bn |
| 2026-08-18 | ₩25,800 | +₩0.8bn | ₩-1.2bn | +₩0.4bn |
| 2026-08-14 | ₩27,250 | +₩0.9bn | ₩-0.8bn | ₩-0.1bn |
| 2026-08-13 | ₩27,050 | ₩-0.8bn | ₩0.0bn | +₩0.7bn |
| 2026-08-12 | ₩27,450 | ₩-0.0bn | +₩0.2bn | ₩-0.2bn |
| 2026-08-11 | ₩26,800 | ₩-1.0bn | ₩-0.5bn | +₩0.7bn |
| 2026-08-10 | ₩26,450 | ₩-0.5bn | +₩0.9bn | ₩-0.3bn |
| 2026-08-07 | ₩25,000 | +₩0.6bn | ₩-0.5bn | ₩-0.1bn |
| 2026-08-06 | ₩24,700 | ₩-1.2bn | +₩0.5bn | +₩0.6bn |
| 2026-08-05 | ₩24,300 | ₩-1.1bn | ₩-0.9bn | +₩1.9bn |
| 2026-08-04 | ₩24,200 | ₩-0.2bn | +₩1.3bn | ₩-1.1bn |
| 2026-08-03 | ₩21,000 | +₩0.2bn | ₩-0.2bn | ₩-0.0bn |
| 2026-07-31 | ₩20,300 | +₩1.6bn | +₩0.3bn | ₩-2.0bn |
| 2026-07-30 | ₩17,900 | +₩0.8bn | ₩-0.0bn | ₩-0.8bn |
| 2026-07-29 | ₩18,130 | ₩-0.4bn | +₩1.0bn | ₩-0.5bn |
| 2026-07-28 | ₩19,900 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-07-27 | ₩22,000 | ₩-0.3bn | +₩0.9bn | ₩-0.6bn |
| 2026-07-24 | ₩21,050 | +₩0.3bn | ₩-0.5bn | +₩0.2bn |
| 2026-07-23 | ₩21,800 | +₩1.1bn | +₩0.5bn | ₩-1.6bn |
| 2026-07-22 | ₩19,350 | +₩0.8bn | ₩-0.6bn | ₩-0.2bn |
| 2026-07-21 | ₩19,460 | +₩0.5bn | ₩-0.3bn | ₩-0.2bn |
| 2026-07-20 | ₩19,750 | +₩1.0bn | ₩-0.6bn | ₩-0.4bn |
| 2026-07-16 | ₩21,150 | +₩0.2bn | ₩-0.6bn | +₩0.4bn |
| 2026-07-15 | ₩22,350 | +₩1.5bn | ₩-0.3bn | ₩-1.2bn |
| 2026-07-14 | ₩21,550 | ₩-0.3bn | +₩0.1bn | +₩0.2bn |
| 2026-07-13 | ₩23,000 | ₩-0.2bn | ₩-0.7bn | +₩1.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.6bn | $-0M | +₩0.2bn | +₩0.3bn |
| 5 days | ₩-1.0bn | $-1M | +₩0.3bn | +₩0.7bn |
| 20 days | +₩2.6bn | +$2M | ₩-1.3bn | ₩-1.4bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Aimed Bio stock?
Over the last 5 sessions foreign investors net sold ₩1.0bn ($1M) of Aimed Bio; over 60 sessions they net bought ₩10.8bn ($8M); since Jan 1, 2026 they net bought ₩14.1bn ($11M). Over 20 sessions the stock is the 108th largest foreign net purchase among 1828 KOSDAQ stocks.
How much of Aimed Bio do foreign investors own?
Foreign investors own 3.03% of Aimed Bio's shares as of Oct 13, 2026. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩1.3bn ($1M) and retail investors net sold ₩1.4bn ($1M) of Aimed Bio. Foreign buying is being met mainly by retail selling.
Is Aimed Bio listed on KOSPI or KOSDAQ?
Aimed Bio (에임드바이오) trades on KOSDAQ under KRX code 0009K0 in the Biotech & Pharma group, with a market capitalization of ₩1T ($1.0B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2025 | ₩47bn ($35M) | – | ₩21bn ($16M) | ₩5bn ($4M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.